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INTRODUCTION
In 1995, the first patients with Parkinson’s disease (PD) who un-
derwent deep brain stimulation (DBS) of the bilateral subtha-
lamic nucleus (STN) were described.1 Currently STN DBS is an 
accepted surgical treatment for the control of PD symptoms in-
adequately controlled by medical therapies.2-5 Numerous stud-
ies, including randomized controlled trials, have demonstrated 
that this procedure can dramatically improve cardinal parkin-
sonian symptoms such as tremors, rigidity, and bradykinesia. 
It has also been demonstrated to improve levodopa-induced 
dyskinesia and reduce the required levodopa dosage for symp-
tom control.2,3,6,7 Levodopa-induced dyskinesia is a frequent 
and important cause of disability in PD and a major reason to 
recommend surgical treatment. In the literature, bilateral STN 
DBS is reported to cause a significant reduction of dyskinesia 
(60% to 80%) in most patients.8-18 Relief from dyskinesia after 
STN DBS has been hypothesized to be due to a postoperative 
reduction of dopaminergic medication;2,7,19-22 however, some 
data suggest that STN DBS may also have direct dyskinesia-
suppressing qualities. The objective of this study was to evalu-
ate the effects of bilateral STN DBS on levodopa-induced dys-
kinesia in patients with PD after surgery, while taking into 
account levodopa dosage reductions.
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MATERIALS AND METHODS
Patients
We retrospectively reviewed the medical records of patients 
with PD who underwent bilateral STN DBS at our institution 
between May 2000 and July 2012. Patients with PD who suf-
fered from severe levodopa-induced peak-dose dyskinesia 
before surgery were included. Patients who previously under-
went thalamotomy or pallidotomy, which may suppress dyski-
nesia, and those who had no postsurgical follow-up for a period 
of 12 months were excluded. Among 137 patients with PD, 100 
were included in the study.
Neurosurgical procedure
Under local anesthesia, implantation of the DBS electrodes was 
performed bilaterally in all patients using a Leksell stereotactic 
frame and magnetic resonance imaging (MRI; Philips MR 
System Achieva, Eindhoven, the Netherlands)-guided target-
ing with Surgiplan (Elekta, Stockholm, Sweden). Initial values 
for STN localization were 12 mm lateral, 2 mm posterior, and 4 
mm inferior to the mid-point between the anterior and posteri-
or commissures. Single-track microelectrode recording (MER) 
using the Microdrive System (Medtronic, Inc., Minneapolis, 
MN, USA) was performed, and cell activity was recorded start-
ing from 15 mm above the STN target. After the precise localiz-
ation of the target point, DBS electrodes (Medtronic 3387; Min-
neapolis, MN, USA) with four contact points were placed in 
such a way that the tip of the electrode was located on the ven-
tral boundary of the STN, passing through the center of the STN. 
Each contact of the DBS electrode was 1.5 mm long, and the 
contacts were 1.5 mm apart from each other. Based on the MER 
results, electrodes were positioned and labeled as follows: 0 
and 1, STN; 2 and 3, the area above the STN (Fig. 1). After satis-
factory outcomes during test stimulations, the position of each 
electrode was verified by postoperative MRI or computed to-
mography that was merged with the preoperatively planned 
target and trajectory. If the actual electrode position was ac-
ceptable, the DBS electrodes were connected to an implant-
able pulse generator (IPG) placed in the subclavicular area un-
der general anesthesia. The patients underwent a single-stage 
operation in which both DBS electrode insertion and IPG im-
plantation were performed on the same day. An efficacy test 
was performed about 1 month after surgery. Over the next 1–2 
months, the contact and stimulation parameters were optimiz-
ed to obtain maximum clinical benefit and minimal side effects.
Clinical evaluation
The outcome assessments consisted of the Unified Parkinson’s 
Disease Rating Scale (UPDRS) part III, UPDRS part IV, and the 
dyskinesia subscore of the UPDRS part IV (items 32 to 34 of UP-
DRS part IV) before surgery and at 12 months postoperatively. 
The UPDRS part III was determined for both the on-medication 
and off-medication states. The off-state was defined as the mo-
tor condition at 8–9 a.m. after at least 12 hours of overnight wi-
thdrawal from anti-parkinsonian medication, while the on-
state was defined as the maximum improvement following a 
dose of levodopa equal to 150% of the patient’s usual first mo-
rning dose. The UPDRS part IV and the dyskinesia subscore of 
the UPDRS part IV were assessed for the on-medication con-
dition during the week prior to surgery. After implantation of 
the DBS device, all scores were assessed for the simulator-on 
condition. Additional information on the levodopa equivalent 
daily dose (LEDD) was obtained, both before surgery and at 12 
months postoperatively. The LEDD was calculated as follows: 
100 mg standard levodopa=133 mg of controlled-release le-
vodopa=10 mg bromocriptine=1 mg pergolide=1 mg prami-
pexole=5 mg ropinirole.
The patients were divided into two groups based on the ch-
ange in their preoperative and 12 months postoperative LEDD: 
Group 1, an LEDD decrease of  >15%, Group 2, all other patients.
All scores from the preoperative and 12-month postoperative 
state were compared to assess improvement between Groups 
1 and 2. The DBS electrode contact used in each Group 2 pa-
Fig. 1. Schematic illustration of the electrode insertion site as described 
in Hamani, et al.36 The 0 and 1 contacts were located in the STN, where-
as the 2 and 3 contacts were located in the area above the STN includ-
ing the zona incerta. AL, ansa lenticularis; CP, cerebral peduncle; FF, 
Field of Forel; GPe, globus pallidus externus; GPi, globus pallidus inter-
nus; H1, H1 Field of Forel (thalamic fasciculus); IC, internal capsule; LF, 
lenticular fasciculus (H2); PPN, pedunculopontine nucleus; Put, puta-
men; SN, substantia nigra; STN, subthalamic nucleus; Thal, thalamus; 
ZI, zona incerta.
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tient was also determined without reducing the LEDD. The lo-
cation of each DBS contact was determined in relation to the 
anterodorsal boundary of the STN, which was identified by 
intraoperative electrophysiological mapping.
Statistical analysis
Student’s t-test was used to determine whether the mean score 
changes differed between Groups 1 and 2. The Mann-Whitney 
U test was used to determine whether the mean improvement 
of dyskinesia differed between patients with stimulation of the 
area above the STN and patients with stimulation of the STN 
itself. All statistical analyses were performed using SPSS (ver-
sion 18.0, SPSS Inc., Chicago, IL, USA). Mean values±standard 
deviation are presented; p values<0.05 were considered statis-
tically significant.
This study was approved by the Institutional Review Board of 
our institution (IRB No. 4-2013-0182).
RESULTS
The patient demographics and clinical characteristics are de-
scribed in Table 1. Of the 100 patients recruited, 67 were in 
Group 1 and 33 in Group 2. The mean ages of the patients at 
surgery were 55.82 and 58.70 years in Groups 1 and 2, respec-
tively. The mean durations of disease before the operation were 
11.13 years for Group 1 and 11.55 years for Group 2. There were 
no significant differences in patient demographics between 
the two groups.
At 12 months after STN DBS, the off-medication motor score 
(UPDRS part III) significantly decreased by 29.19% for Group 
1 and 22.32% for Group 2. The on-medication motor score sl-
ightly decreased by 8.95% in Group 1, whereas in Group 2 it in-
creased by 5.12%. There were no significant differences in the 
mean motor score changes between the groups in the on-me-
dication (p=0.276) and off-medication states (p=0.123). The 
mean improvements of the UPDRS part IV score for Groups 1 
and 2 after 12 months were 23.25% and 23.17%, respectively. 
No differences were observed in the mean UPDRS part IV score 
changes between the groups (p=0.993). The dyskinesia sub-
scores were 4.30±2.43 at baseline and 1.87±2.52 at 12 months 
after surgery in Group 1, and the corresponding respective sc-
ores were 4.33±2.78 and 1.85±2.31 in Group 2. Mean dyskine-
sia subscore changes after 12 months were 61.90% and 57.14% 
for Groups 1 and 2, respectively. Group 1 was more likely than 
Group 2 to have an improvement of dyskinesia. However, the 
difference in dyskinesia improvement between the groups was 
not statistically significant (p=0.619) (Table 2).
Analysis of Group 2 revealed that 18 patients had an active 
contact above the STN, including within the zona incerta, and 
15 patients had an active contact within the STN. The mean im-
provements of the dyskinesia subscores in patients with stim-
ulation above the STN and within the STN after 12 months 
were 73.57% and 37.44%, respectively. Dyskinesia was signifi-
cantly attenuated by stimulation of the area above the STN in 
18 patients when compared to stimulation of the STN itself in 
15 patients (p=0.048) (Fig. 2).
DISCUSSION
In this study, levodopa-induced peak-dose dyskinesia was re-
duced following bilateral STN DBS in all groups. This clearly 
shows that bilateral STN DBS can be a good therapeutic option 
for the treatment of dyskinesia.
Previous studies have also reported an improvement of le-
vodopa-induced peak-dose dyskinesia following bilateral STN 
DBS. A randomized controlled trial by Odekerken, et al.6 dem-
onstrated that the severity of on-phase dyskinesia, as assessed 
by the clinical dyskinesia rating scale (range 0–28), showed 
profound and significant changes from baseline (4.8) to 12 
months after STN DBS (3.8). They noted that the levodopa dos-
age was reduced from 1254 mg/day preoperatively to 708 mg/
day postoperatively. Another study by Portman, et al.2 reported 
that the severity of on-medication dyskinesia clearly improved 
by 57% 12 months after STN DBS. They noted that surgery re-
Table 1. Clinical Characteristics of Patients
Characteristic Group 1 Group 2 p value
No. of patients 67 33
Male:female 34:33 11:22
Age at surgery (yrs)* 55.82±9.08 58.70±8.86 0.964
Disease duration (yrs)* 11.13±4.66 11.55±5.15 0.496
*Presented as mean±standard deviation.
Table 2. Patient Outcomes
Baseline 12 months after surgery Mean improvement in score (%)
Group 1 Group 2 Group 1 Group 2 Group 1 Group 2 p value
UPDRS III (off)* 41.55±13.90 41.97±12.98 28.00±12.16 31.27±13.96 29.19±27.40 22.32±33.45 0.276
UPDRS III (on)* 19.64±9.51 16.67±9.01 18.01±9.11 18.85±11.28 8.95±39.95 -5.12±47.59 0.123
UPDRS IV* 8.13±4.41 6.97±3.85 5.79±3.36 4.85±3.82 23.25±42.97 23.17±48.79 0.993
Dyskinesia subscore* 4.30±2.43 4.33±2.78 1.87±2.52 1.85±2.31 61.90±42.67 57.14±49.17 0.619
LEDD* 1120.54±460.76 746.74±407.01 402.31±284.04 828.48±368.41 62.31±22.59 -23.08±52.41 0.000
UPDRS, Unified Parkinson’s Disease Rating Scale; LEDD, levodopa equivalent daily dose.
*Presented as mean±standard deviation.
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sulted in a marked reduction of anti-parkinsonian medication 
(-39%) and consequently reduced the severity of peak-dose 
dyskinesia dramatically.
There has been some discussion regarding the mechanisms 
underlying the effect of STN DBS on levodopa-induced dyski-
nesia in patients with PD. The majority of researchers opine 
that the significant postoperative reduction of dyskinesia is 
caused by a significant postoperative reduction of levodopa 
medication.2,7,19-22 In contrast to previous studies, the results of 
this study demonstrated that dyskinesia was improved even 
though the medication was unchanged, or increased, after sur-
gery. Importantly, in PD patients with STN DBS, the improve-
ment in dyskinesia (≈70%) was larger than the reduction in le-
vodopa dose (35–40%) unlike for other complications. Only 
case reports and small series have been published about the 
direct effect of STN DBS on levodopa-induced dyskinesia (Ta-
ble 3). Krack, et al.23 reported that high-frequency stimulation 
of the STN reduced the severity of peak-dose dyskinesia by 
30% in response to a suprathreshold dose of levodopa. Øster-
gaard, et al.3 described an 86% reduction in the duration of dys-
kinesia 12 months after bilateral STN DBS. In their study, daily 
levodopa dose equivalents were reduced only by 19%, which is 
a smaller reduction than in other similar studies. Katayama, et 
al.24 analyzed the direct effect of STN DBS on peak-dose dyski-
nesia during a 2-week period after surgery without reducing 
the levodopa dosage. They noted that the peak-dose dyskine-
sia was quickly attenuated by bipolar stimulation in 8 (18%) of 
the 45 patients. They also reported that dyskinesia was never at-
tenuated by stimulation of the area above the STN. Combining 
our findings with those of the aforementioned studies, the im-
provement of levodopa-induced dyskinesia could be related 
directly to the effect of bilateral STN DBS.
It has been difficult to demonstrate a role for the STN in the 
cancellation of dyskinesia beyond the reduction in daily levo-
dopa dose in patients. Several explanations could account for 
the direct antidyskinetic effect of STN DBS on levodopa-in-
duced dyskinesia. First, most studies suggested that stimulat-
ing pallidothalamic, pallidosubthalamic, or subthalamopalli-
dal fibers, which are densely distributed above the STN, can 
cause effects similar to those of thalamic or pallidal DBS.8,24-26 
In particular, the lenticular fasciculus, which lies between the 
STN inferiorly and the zona incerta superiorly, is a white mat-
ter tract from the dorsal globus pallidus interna (GPi). This tract 
transverses the internal capsule and then combines with the 
ansa lenticularis (the ventral GPi outflow tracts) to form the 
thalamic fasciculus in the field H1 of Forel, which then termi-
nates at the ventroanterior/ventrolateral (VA/VL) thalamic 
nuclei.8,27,28 Therefore, modulation of these fibers may induce 
an effect similar to that of GPi DBS or Forel’s field surgery. The 
results of this study also revealed larger improvements in dyski-
nesia with stimulation of the area above the STN than with 
stimulation of the STN itself, which is consistent with previous 
findings. Second, some authors have indicated that the anti-
dyskinetic response after STN DBS could be attributed to the 
Fig. 2. The mean improvement of dyskinesia was reduced by 73.57% (from 
3.44 preoperatively to 0.83 postoperatively) in patients with stimulation of 
the area above the STN, whereas the mean improvement of dyskinesia 
was reduced by only 37.44% (from 5.40 preoperatively to 3.07 postopera-
tively) in patients where the STN was directly stimulated. There was a 
significant difference between stimulation of the area above the STN and 
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Table 3. Comparison of Studies of Subthalamic Deep Brain Stimulation on Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease
Author, yr of publication Patients Improvement in dyskinesia
Figueiras-Méndez, et al., 199934 68-yr-old patient
The dyskinesia score was 15 when the stimulation was off and decreased immediately to 2 when 
  the stimulation was switched on. The anti-parkinsonian therapy was maintained.
Krack, et al., 199923 8 patients
The severity of peak-dose dyskinesia was reduced by 30% using the same suprathreshold dose as 
  before the operation.
Østergaard, et al., 20023 26 patients
The results showed a significant reduction of 86% in the duration of dyskinesia. Daily levodopa dose 
  equivalents were reduced by only 19%.
Katayama, et al., 200624 45 patients
Almost complete control of the peak-dose dyskinesia was observed in 24 (53%) of the 45 patients 
  without reducing the levodopa dosage during the early period after surgery.
Herzog, et al., 20078 3 patients
In two of three patients, additional stimulation of a proximal contact located within the subthalamic 
  white matter may lead to a significant reduction of dyskinesia associated with STN DBS.
Nishikawa, et al., 201025 71-yr-old patient
Using contact 2 as the cathode, levodopa-induced dyskinesia was markedly attenuated. The patient 
  received the same doses of anti-parkinsonian drugs as preoperatively.
Oyama, et al., 201235 75 patients Despite no change in medication, 11.9% of STN DBS subjects had dyskinesia suppression.
STN, subthalamic nucleus.
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effect of continuous high-frequency electrical stimulation in 
the target.22,23,29 Thus, STN surgery could induce a stable and 
continuous functional state with reduced fluctuations in basal 
ganglia activity, which mimics the effect of continuous dopa-
mine stimulation, a process that occurs during the infusion of 
dopamine receptor agonists.23,30,31 Krack, et al.23 described the 
effect of chronic high-frequency stimulation of the STN on 
peak-dose dyskinesia as being related directly to the function-
al inhibition of the STN and indirectly to the replacement of 
pulsatile dopaminergic stimulation by continuous functional 
inhibition of the STN. The results of their study are supported 
by previous observations from Nimura, et al.,32 who measured 
synaptic dopamine levels in the striatum using positron emis-
sion tomography with [11C]raclopride. They reported that DBS 
of the STN induces the stabilization of synaptic dopamine con-
centrations in the striatum and may contribute to the allevia-
tion of levodopa-related motor fluctuations. A third possible 
mechanism is related to a dopaminergic bundle that courses 
through the anatomic space between the zona incerta and the 
STN, traveling along the lenticular fasciculus caudally and the 
ansa lenticularis rostrally.27,33 Direct stimulation of this bundle 
could result in an anti-dopaminergic effect by a depolarization 
blockage of the axons.27
In conclusion, this study confirms the efficacy of STN DBS in 
ameliorating levodopa-induced dyskinesia in PD regardless of 
whether the levodopa dosage was reduced. Further, the impro-
vement in levodopa-induced dyskinesia following stimulation 
of the area above the STN was larger than that after stimulation 
of the STN. Thus, in future studies, we would like to attempt si-
multaneous stimulation of both the STN and the area above 
the STN in order to diminish both the cardinal symptoms of 
PD and levodopa-induced dyskinesia. This combined stimu-
lation can be performed using a single quadripolar electrode.
Although this was an unblinded retrospective study, it sup-
ports findings from previous studies investigating direct dys-
kinesia suppression by STN DBS. Further studies on the direct 
antidyskinetic effect of STN DBS in larger groups are needed 
to investigate the mechanism of STN DBS in patients with le-
vodopa-induced dyskinesia.
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